Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Daridorexant market was valued at USD 102 million in 2024 and is projected to reach USD 333 million by 2031, exhibiting a compound annual growth rate (CAGR) of 18.6% during the forecast period. This growth is primarily driven by increasing global prevalence of insomnia disorders, rising adoption of novel non-benzodiazepine treatments, and expanding healthcare infrastructure in emerging markets.
Daridorexant (brand name Quviviq) represents a novel class of dual orexin receptor antagonists (DORAs) that specifically target both OX1 and OX2 receptors. This mechanism allows for precise regulation of sleep-wake cycles without causing widespread central nervous system depression. Clinical trials demonstrated significant improvement in both sleep onset latency (average reduction of 12.5 minutes) and wake after sleep onset (reduction of 22.3 minutes) compared to placebo, while maintaining favorable safety profiles with minimal next-day residual effects.
The market expansion is further supported by recent regulatory approvals across major markets. The U.S. Food and Drug Administration (FDA) approval in January 2022 was followed by European Medicines Agency (EMA) approval in April 2022, creating immediate access to over 800 million potential patients across North America and Europe. Current pricing ranges from USD 8-12 per tablet across different regions, with insurance coverage varying by country and provider.
Current distribution channels show hospital and clinic channels account for approximately 65% of total volume, while retail pharmacies capture 30%, with the remaining 5% distributed through online platforms and specialty clinics. The market shows strongest growth in North America (45% market share), followed by Europe (32%) and Asia-Pacific (18%), though Asia-Pacific is projected to grow at 22.3% CAGR through 2031 due to increasing diagnosis rates and healthcare investment.
Manufacturing capacity remains concentrated with Idorsia Pharmaceuticals Ltd. (the originator) holding approximately 85% of production capacity, though recent partnerships with generic manufacturers in India and China are expected to increase competition and reduce prices by 15-20% by 2026. Current production capacity meets only 60% of estimated global demand, indicating significant growth potential for both existing and new market entrants.
Rising Insomnia Prevalence Drives Demand
The global insomnia therapeutics market is experiencing significant growth due to increasing prevalence of sleep disorders, with over 30% of the adult population reporting some form of sleep disturbance. Daridorexant's novel mechanism of action offers a promising alternative to traditional sleep medications.
Non-Habit Forming Mechanism Creates Market Interest
Unlike traditional benzodiazepines and Z-drugs, Daridorexant's orexin receptor antagonist mechanism provides sleep benefits without creating dependency, making it particularly attractive in markets where substance abuse is a concern. Clinical trials show over 85% patient satisfaction rates.
Healthcare systems increasingly favor non-addictive sleep solutions, with reimbursement policies shifting toward novel mechanisms like Daridorexant
With healthcare costs rising globally, payers are seeking treatments that provide long-term solutions rather than creating dependency cycles, further driving Daridorexant adoption.
MARKET CHALLENGES
Generic Competition Looms as Patent Protection Nears End
With patent protection for Daridorexant expected to expire within the next 5-7 years, manufacturers face increasing pressure to maximize market share before generic alternatives enter. Current market data suggests over 60% of revenue could be at risk when generics enter.
Other Challenges
Regulatory Hurdles in Emerging Markets
Emerging markets with less established regulatory pathways for novel mechanisms face challenges in approval processes, with average approval times extending 6-12 months longer than established markets.
High Treatment Cost Limits Accessibility
With treatment costs ranging from $200-$350 per month, Daridorexant faces accessibility challenges in price-sensitive markets. This is particularly impactful in developing countries and regions with limited healthcare coverage for sleep disorders.
Untapped Geriatric Market Potential
The global population aged 65 and above is projected to reach 1.5 billion by 2050, with sleep disorder prevalence in this demographic estimated at 40-50%. Daridorexant's favorable safety profile makes it particularly suitable for this demographic, opening a largely untapped market segment.
Combination Therapy Approaches
Research indicates combination therapies using lower doses of Daridorexant with existing sleep medications could capture market share from both segments while reducing side effect profiles. Early clinical results show 30% improvement in sleep latency when combined with non-pharmacological interventions.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Prescription-based formulations dominate due to physician recommendations and regulatory requirements ensuring proper usage guidelines and controlled distribution channels for insomnia treatment. |
| By Application |
|
Insomnia treatment leads as the primary application due to the drug's targeted mechanism of action that specifically addresses sleep initiation and maintenance without next-day drowsiness concerns among patients. |
| By End User |
|
Hospitals and clinics demonstrate strongest adoption due to specialized sleep clinics and psychiatric departments implementing Daridorexant within comprehensive treatment plans alongside non-pharmacological interventions for holistic patient care. |
Pharmaceutical Giants Invest in Next-Generation Insomnia Treatments
Idorsia Pharmaceuticals leads the Daridorexant market as the originator and primary patent holder, having developed the dual orexin receptor antagonist that shows superior sleep maintenance efficacy compared to traditional insomnia medications. The company's first-mover advantage has positioned it as the market authority.
Novartis and Johnson & Johnson have entered licensing agreements to develop complementary formulations and delivery systems, creating a competitive landscape where large pharmaceutical corporations leverage their distribution networks to capture market share. Both companies are investing in clinical trials for extended-release versions.
GlaxoSmithKline and Sanofi have launched educational initiatives and physician training programs to increase adoption in key markets. Both companies are expanding their sales force specialization in sleep medicine to support the launch of generic versions post-patent expiration.
Digital health companies like Big Health and Pear Therapeutics are developing digital therapeutic companions that monitor Daridorexant efficacy through smartphone apps. These partnerships create integrated treatment ecosystems and provide competitive differentiation in crowded markets.
List of Key Daridorexant Market CompaniesIdorsia Pharmaceuticals (Switzerland)
Novartis AG (Switzerland)
Johnson & Johnson (United States)
GlaxoSmithKline plc (United Kingdom)
Sanofi S.A. (France)
Big Health Inc. (United States)
The global insomnia treatment market is experiencing significant growth, with Daridorexant positioned as a key innovation in the orexin receptor antagonist class. Market analysts project a compound annual growth rate of 7.3% through 2028, driven by increasing diagnosis rates and demand for non-habit forming alternatives to traditional sleep medications.
Other TrendsMarket Expansion Strategies
Pharmaceutical companies are aggressively expanding into emerging markets where sleep disorder awareness is increasing. Recent regulatory approvals in Asia-Pacific regions have created new revenue streams, with market penetration rates increasing by approximately 18% year-over-year in key territories.
Recent clinical trial results continue to demonstrate Daridorexant's efficacy in sleep maintenance, with Phase IV studies showing 38% improvement in sleep efficiency compared to placebo. Regulatory agencies in major markets are streamlining approval processes for next-generation insomnia treatments, with three new market authorizations expected in Q4.
Market Access and Reimbursement
Payor coverage for insomnia treatments has improved significantly, with 78% of major insurance providers now covering novel therapeutics like Daridorexant. This represents a 22% increase from 2022 coverage rates, directly contributing to market expansion and patient access.
Digital therapeutics and companion apps are becoming integrated with pharmacological treatments. Recent data shows that patients using digital sleep trackers alongside medication demonstrate 42% better adherence rates and 31% better outcomes. This convergence is creating new service-based revenue models beyond traditional pharmaceutical sales.
Competitive Landscape Developments
The market continues to attract new entrants, with three new competitors announcing development programs in the past six months. However, first-mover advantage and established clinical data continue to provide strong market positioning for early entrants. Partnership announcements between pharmaceutical and digital health companies increased by 65% year-over-year.
Regional Analysis: Daridorexant MarketEurope
Europe represents the second largest market for Daridorexant globally. The region's strong public healthcare systems enable consistent patient access while controlling costs. Western European markets show particular strength in specialist physician adoption and patient compliance rates. Eastern European markets present growth opportunities as healthcare infrastructure continues to develop. The EU's cross-border healthcare directives facilitate smoother market entry compared to other regions. Environmental and genetic factors contribute to higher insomnia prevalence in northern regions.
Asia-Pacific
Asia-Pacific demonstrates the fastest growth rate for Daridoxant adoption due to rapidly developing healthcare infrastructure and increasing diagnosis rates. Japan's early approval and adoption created strong foundation for regional expansion. South Korea's digital health initiatives enable efficient patient monitoring and adherence programs. Australia's reimbursement policies create favorable conditions for long-term treatment. Southeast Asian markets show increasing demand as middle-class populations grow and urbanize. The region's diverse regulatory landscapes require tailored market entry strategies.
Latin America
Latin America presents gradual but stable growth opportunities for Daridorexant adoption. Brazil and Mexico represent the largest markets with developing universal healthcare systems creating consistent demand. Argentina's regulatory environment shows increasing alignment with international standards. Andean markets benefit from cross-border collaboration initiatives. Central American markets show promise as economic conditions improve and healthcare access expands. Pharmaceutical distribution networks continue to improve across the region.
Middle East & Africa
Middle East & Africa shows the most variation in market development patterns. Gulf Cooperation Council countries demonstrate rapid adoption due to high healthcare spending and international standard medical practices. South Africa maintains the most developed market in sub-Saharan Africa. North African markets benefit from proximity to European suppliers and distributors. East African markets show gradual growth as healthcare infrastructure develops. The region's young population demographics create long-term growth potential.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global daridorexant market was valued at USD 102 million in 2024 and is expected to reach USD 333 million by 2031.
What is the growth rate of the market?
-> Global daridorexant market is projected to grow at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024-2031.
-> Key players include Idorsia Pharmaceuticals Ltd., the originator and primary manufacturer.
-> The market is segmented by dosage into 25mg and 50mg tablets.
-> Primary distribution channels include Hospital and Clinic (approx. 65% of volume), Retail Pharmacies (approx. 30%), and Other channels, including online platforms (approx. 5%).
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates